Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:32 am
Author: Getaka|Social: XLinkedIn

Procter & Gamble Health Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹3,031.21Overvalued by 36.97%vs CMP ₹4,809.00

P/E (27.2) × ROE (36.4%) × BV (₹373.00) × DY (2.60%)

₹2,108.94Overvalued by 56.15%vs CMP ₹4,809.00
MoS: -128% (Negative)Confidence: 66/100 (Moderate)Models: 1 Fair, 9 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹3,297.9320%Over (-31.4%)
Graham NumberEarnings₹1,218.1514%Over (-74.7%)
Earnings PowerEarnings₹1,126.7312%Over (-76.6%)
DCFCash Flow₹2,790.9412%Over (-42%)
Net Asset ValueAssets₹373.496%Over (-92.2%)
EV/EBITDAEnterprise₹2,425.288%Over (-49.6%)
Dividend DiscountDividends₹4,418.528%Fair (-8.1%)
Earnings YieldEarnings₹1,768.106%Over (-63.2%)
ROCE CapitalReturns₹984.258%Over (-79.5%)
Revenue MultipleRevenue₹843.975%Over (-82.5%)
Consensus (10 models)₹2,108.94100%Overvalued
Key Drivers: Wide model spread (₹373–₹4,419) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 8.8%

*Investments are subject to market risks

Investment Snapshot

72
Procter & Gamble Health Ltd scores 72/100 (Strong)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health88/100 · Strong
ROCE 47.8% ExcellentROE 36.4% ExcellentD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money60/100 · Moderate
FII holding up 0.11% (6mo) Slight increasePromoter holding at 51.8% Stable
Earnings Quality65/100 · Strong
OPM expanding (25% → 31%) Improving
Quarterly Momentum58/100 · Moderate
Revenue (4Q): +16% YoY GrowingProfit (4Q): +24% YoY PositiveOPM: 30.0% (down 10.0% YoY) Margin pressure
Industry Rank80/100 · Strong
P/E 27.2 vs industry 53.8 Cheaper than peersROCE 47.8% vs industry 16.4% Above peersROE 36.4% vs industry 15.2% Above peers3Y sales CAGR: -6% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:32 am

Market Cap 7,983 Cr.
Current Price 4,809
Intrinsic Value₹2,108.94
High / Low 6,739/4,725
Stock P/E27.2
Book Value 373
Dividend Yield2.60 %
ROCE47.8 %
ROE36.4 %
Face Value 10.0
PEG Ratio3.09

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Procter & Gamble Health Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Procter & Gamble Health Ltd 7,983 Cr. 4,809 6,739/4,72527.2 3732.60 %47.8 %36.4 % 10.0
Marksans Pharma Ltd 7,615 Cr. 168 271/15521.1 59.30.48 %20.0 %16.8 % 1.00
Sanofi India Ltd 7,513 Cr. 3,262 6,718/3,15121.7 3262.30 %57.5 %43.0 % 10.0
Shilpa Medicare Ltd 7,328 Cr. 375 502/26041.4 1250.13 %7.82 %4.21 % 1.00
Sequent Scientific Ltd 8,768 Cr. 201 260/111203 32.20.00 %8.47 %3.21 % 2.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Procter & Gamble Health Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 310321301305310252284313310311339325374
Expenses 201241256216208185236199186230248205263
Operating Profit 10980458910267481141238190120110
OPM % 35%25%15%29%33%27%17%36%40%26%27%37%30%
Other Income 555652-18343454
Interest 0000000000000
Depreciation 8666777665566
Profit before tax 10579448810063231111227989119109
Tax % 27%25%32%26%28%26%26%26%25%22%25%26%29%
Net Profit 77593066724717829161668978
EPS in Rs 46.2735.6617.9639.5043.4228.0510.1149.6054.7636.8639.8753.3446.74

Last Updated: March 3, 2026, 3:16 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 12:16 pm

MetricDec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020n n 18mJun 2021Jun 2022Jun 2023Jun 2024Mar 2025n n 16mTTM
Sales 8679409936988499271,3561,0091,1141,2301,1519341,349
Expenses 8098558776217017231,037762846905845616947
Operating Profit 598511677148204319246268325307319402
OPM % 7%9%12%11%17%22%24%24%24%26%27%34%30%
Other Income 202224747684866181318-51016
Interest 0000000101100
Depreciation 13232519211729302728271723
Profit before tax 6783115132895234355233253314273312395
Tax % 35%36%31%29%6%32%28%24%24%27%26%25%
Net Profit 43547994839159254177193229201234293
EPS in Rs 26.0432.2747.6756.57505.2795.64153.07106.51115.98138.24121.08141.22176.81
Dividend Payout % 23%23%23%27%87%0%150%122%45%69%215%89%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year
YoY Net Profit Growth (%)
Change in YoY Net Profit Growth (%)

No data available for trend analysis.

Growth

Compounded Sales Growth
10 Years:1%
5 Years:0%
3 Years:-3%
TTM:11%
Compounded Profit Growth
10 Years:18%
5 Years:8%
3 Years:10%
TTM:43%
Stock Price CAGR
10 Years:24%
5 Years:6%
3 Years:14%
1 Year:24%
Return on Equity
10 Years:28%
5 Years:27%
3 Years:33%
Last Year:36%

Last Updated: September 5, 2025, 12:40 pm

Balance Sheet

Last Updated: February 1, 2026, 3:46 am

MonthDec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025Sep 2025
Equity Capital 17171717171717171717171717
Reserves 5385756477171,524800890687600734522520603
Borrowings 000000083121086
Other Liabilities 154192215258219250269275269338247250268
Total Liabilities 7087848799911,7591,0671,1769868881,101794794894
Fixed Assets 110132111115104101101104112144128116106
CWIP 28730917112139413261113
Investments 24422870000000000
Other Assets 5476037117971,6399541,053843736925660667776
Total Assets 7087848799911,7591,0671,1769868881,101794794894

Reserves and Borrowings Chart

Cash Flow

MonthDec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025
Cash from Operating Activity + 58310754-130235247170236228169
Cash from Investing Activity + 11-68-75-481,270165-32-26-22-710
Cash from Financing Activity + -17-12-15-22-30-883-387-289-98-418-235
Net Cash Flow -1417-161,109-483-172-145116-197-56
Free Cash Flow -35387524-157212196132198207168
CFO/OP 66%136%138%147%117%106%128%87%100%102%78%

Free Cash Flow

MonthDec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020n n 18mJun 2021Jun 2022Jun 2023Jun 2024Mar 2025n n 16m
Free Cash Flow59.0085.00116.0077.00148.00204.00319.00238.00265.00313.00297.00319.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthDec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025
Debtor Days 444939642830262227342757
Inventory Days 162140145243154139113138124136120152
Days Payable 405567128124106105209185239184239
Cash Conversion Cycle 166134118179586334-49-34-69-37-30
Working Capital Days 74695294422223717151948
ROCE %12%15%18%16%78%20%29%29%38%45%45%48%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%
FIIs 6.72%7.15%7.38%7.60%6.24%6.39%6.61%7.01%6.86%6.99%7.24%6.97%
DIIs 12.31%12.29%12.30%12.66%13.72%14.56%14.84%14.71%14.21%14.15%13.90%13.84%
Public 29.14%28.74%28.50%27.92%28.22%27.24%26.74%26.47%27.11%27.03%27.05%27.37%
No. of Shareholders 61,03058,85657,91956,73056,77855,92354,79253,73653,99352,47850,00649,302

Shareholding Pattern Chart

No. of Shareholders

Procter & Gamble Health Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Nippon India Small Cap Fund 692,659 0.56 367.32596,8072025-12-08 07:42:1316.06%
ICICI Prudential Smallcap Fund 365,000 2.38 193.56362,7662026-02-22 23:27:480.62%
ICICI Prudential Bharat Consumption Fund 22,192 0.38 11.7722,4422026-01-25 11:07:48-1.11%
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund 16,778 0.13 8.971,4712026-02-22 23:27:49-76.52%
HDFC Retirement Savings Fund - Hybrid Equity 12,000 0.37 6.36N/AN/AN/A
ICICI Prudential MNC Fund 6,730 0.21 3.57N/AN/AN/A
Sundaram Long Term Micro Cap Tax Advantage Fund - Series III 3,653 2.73 1.94N/AN/AN/A
Sundaram Long Term Micro Cap Tax Advantage Fund - Series VI 1,831 2.84 0.97N/AN/AN/A
Sundaram Long Term Tax Advantage Fund - Series III 1,748 2.89 0.93N/AN/AN/A
Sundaram Long Term Micro Cap Tax Advantage Fund - Series IV 1,708 2.67 0.91N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Jun 24Jun 23Jun 22Jun 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 141.00133.00138.00116.00107.00
Diluted EPS (Rs.) 141.00121.00138.00116.00107.00
Cash EPS (Rs.) 151.26137.58155.16132.29124.60
Book Value[Excl.RevalReserv]/Share (Rs.) 323.47324.24452.34371.38423.92
Book Value[Incl.RevalReserv]/Share (Rs.) 323.47324.24452.34371.38423.92
Dividend / Share (Rs.) 125.00260.0095.0052.50130.00
Revenue From Operations / Share (Rs.) 562.75693.53740.73671.33607.67
PBDIT / Share (Rs.) 198.04193.75206.67169.20159.11
PBIT / Share (Rs.) 187.98177.25189.74152.88141.01
PBT / Share (Rs.) 187.72164.65189.28152.63140.53
Net Profit / Share (Rs.) 141.21121.07138.23115.97106.51
PBDIT Margin (%) 35.1927.9327.9025.2026.18
PBIT Margin (%) 33.4025.5525.6122.7723.20
PBT Margin (%) 33.3523.7425.5522.7323.12
Net Profit Margin (%) 25.0917.4518.6617.2717.52
Return on Networth / Equity (%) 43.6537.3430.5531.2225.12
Return on Capital Employeed (%) 53.9051.1339.5038.5731.32
Return On Assets (%) 29.5125.3020.8321.5417.92
Asset Turnover Ratio (%) 1.181.211.231.190.93
Current Ratio (X) 2.442.392.622.603.04
Quick Ratio (X) 1.941.902.182.112.55
Inventory Turnover Ratio (X) 8.552.382.552.772.29
Dividend Payout Ratio (NP) (%) 99.14206.4840.87147.43215.93
Dividend Payout Ratio (CP) (%) 92.55181.7136.41129.25184.57
Earning Retention Ratio (%) 0.86-106.4859.13-47.43-115.93
Cash Earning Retention Ratio (%) 7.45-81.7163.59-29.25-84.57
Interest Coverage Ratio (X) 764.51446.71445.55668.74330.15
Interest Coverage Ratio (Post Tax) (X) 546.14308.18299.01459.38222.00
Enterprise Value (Cr.) 8347.678138.398273.456626.398817.13
EV / Net Operating Revenue (X) 8.947.076.735.958.74
EV / EBITDA (X) 25.3925.3024.1223.5933.38
MarketCap / Net Operating Revenue (X) 9.147.287.096.249.21
Retention Ratios (%) 0.85-106.4859.12-47.43-115.93
Price / BV (X) 15.9015.5711.6011.2813.20
Price / Net Operating Revenue (X) 9.147.287.096.249.21
EarningsYield 0.020.020.020.020.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Procter & Gamble Health Ltd. is a Public Limited Listed company incorporated on 26/04/1967 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1967PLC013726 and registration number is 013726. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 934.17 Cr. and Equity Capital is Rs. 16.60 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsP&G Plaza, Cardinal Gracias Road, Mumbai Maharashtra 400009Contact not found
Management
NamePosition Held
Mr. S MadhavanChairman & Ind.Director
Mr. Milind ThatteManaging Director
Mr. Lokesh ChandakExecutive Director & CFO
Ms. Seema SambasivanNon Executive Director
Mr. Aalok AgrawalNon Executive Director
Ms. Krishna SarmaIndependent Director
Mr. Sharad TyagiIndependent Director

FAQ

What is the intrinsic value of Procter & Gamble Health Ltd and is it undervalued?

As of 12 April 2026, Procter & Gamble Health Ltd's intrinsic value is ₹2108.94, which is 56.15% lower than the current market price of ₹4,809.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (36.4 %), book value (₹373), dividend yield (2.60 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Procter & Gamble Health Ltd?

Procter & Gamble Health Ltd is trading at ₹4,809.00 as of 12 April 2026, with a FY2026-2027 high of ₹6,739 and low of ₹4,725. The stock is currently near its 52-week low. Market cap stands at ₹7,983 Cr..

How does Procter & Gamble Health Ltd's P/E ratio compare to its industry?

Procter & Gamble Health Ltd has a P/E ratio of 27.2, which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Procter & Gamble Health Ltd financially healthy?

Key indicators for Procter & Gamble Health Ltd: ROCE of 47.8 % indicates efficient capital utilization; ROE of 36.4 % shows strong shareholder returns. Dividend yield is 2.60 %.

Is Procter & Gamble Health Ltd profitable and how is the profit trend?

Procter & Gamble Health Ltd reported a net profit of ₹234 Cr in Mar 2025n n 16m on revenue of ₹934 Cr. Compared to ₹193 Cr in Jun 2022, the net profit shows an improving trend.

Does Procter & Gamble Health Ltd pay dividends?

Procter & Gamble Health Ltd has a dividend yield of 2.60 % at the current price of ₹4,809.00. This is a relatively attractive yield for income-seeking investors.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Procter & Gamble Health Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports